Epigenetic upregulation of Schlafen11 renders 
WNT- and SHH-activated medulloblastomas sensitive to cisplatin

• Published in: Neuro-oncology (Charlottesville, Va.) Vol. 25; no. 5; pp. 899 - 912
• Main Authors: Nakata, Satoshi, Murai, Junko, Okada, Masayasu, Takahashi, Haruhiko, Findlay, Tyler H, Malebranche, Kristen, Parthasarathy, Akhila, Miyashita, Satoshi, Gabdulkhaev, Ramil, Benkimoun, Ilan, Druillennec, Sabine, Chabi, Sara, Hawkins, Eleanor, Miyahara, Hiroaki, Tateishi, Kensuke, Yamashita, Shinji, Yamada, Shiori, Saito, Taiki, On, Jotaro, Watanabe, Jun, Tsukamoto, Yoshihiro, Yoshimura, Junichi, Oishi, Makoto, Nakano, Toshimichi, Imamura, Masaru, Imai, Chihaya, Yamamoto, Tetsuya, Takeshima, Hideo, Sasaki, Atsuo T, Rodriguez, Fausto J, Nobusawa, Sumihito, Varlet, Pascale, Pouponnot, Celio, Osuka, Satoru, Pommier, Yves, Kakita, Akiyoshi, Fujii, Yukihiko, Raabe, Eric H, Eberhart, Charles G, Natsumeda, Manabu
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 04.05.2023; Oxford University Press (OUP)
• Subjects: Basic and Translational Investigations; Cerebellar Neoplasms - drug therapy; Cerebellar Neoplasms - genetics; Cisplatin - pharmacology; Epigenesis, Genetic; Hedgehog Proteins - genetics; Hedgehog Proteins - metabolism; Humans; Irinotecan; Life Sciences; Medulloblastoma - drug therapy; Medulloblastoma - genetics; Nuclear Proteins - metabolism; Up-Regulation; DNA damaging agent; medulloblastoma; SLFN11
• ISSN: 1522-8517; 1523-5866
• DOI: 10.1093/neuonc/noac243

Abstract Background Intensive chemotherapeutic regimens with craniospinal irradiation have greatly improved survival in medulloblastoma patients. However, survival markedly differs among molecular subgroups and their biomarkers are unknown. Through unbiased screening, we found Schlafen family member 11 (SLFN11), which is known to improve response to DNA damaging agents in various cancers, to be one of the top prognostic markers in medulloblastomas. Hence, we explored the expression and functions of SLFN11 in medulloblastoma. Methods SLFN11 expression for each subgroup was assessed by immunohistochemistry in 98 medulloblastoma patient samples and by analyzing transcriptomic databases. We genetically or epigenetically modulated SLFN11 expression in medulloblastoma cell lines and determined cytotoxic response to the DNA damaging agents cisplatin and topoisomerase I inhibitor SN-38 in vitro and in vivo. Results High SLFN11 expressing cases exhibited significantly longer survival than low expressing cases. SLFN11 was highly expressed in the WNT-activated subgroup and in a proportion of the SHH-activated subgroup. While WNT activation was not a direct cause of the high expression of SLFN11, a specific hypomethylation locus on the SLFN11 promoter was significantly correlated with high SLFN11 expression. Overexpression or deletion of SLFN11 made medulloblastoma cells sensitive and resistant to cisplatin and SN-38, respectively. Pharmacological upregulation of SLFN11 by the brain-penetrant histone deacetylase-inhibitor RG2833 markedly increased sensitivity to cisplatin and SN-38 in SLFN11-negative medulloblastoma cells. Intracranial xenograft studies also showed marked sensitivity to cisplatin by SLFN11-overexpression in medulloblastoma cells. Conclusions High SLFN11 expression is one factor which renders favorable outcomes in WNT-activated and a subset of SHH-activated medulloblastoma possibly through enhancing response to cisplatin.